As of November 7, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Vir Biotechnology, Inc. The largest reported stake is BlackRock, Inc.'s, at 12.4%. 9 filings are on record since February 17, 2026 (Schedule 13G/A, October 27, 2026).
Sell to companies like Vir Biotechnology, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: ARCH Venture Fund IX, L.P. · Sole voting: 0 · Shared voting: 11,897,988 · Sole dispositive: 0 · Shared dispositive: 11,897,988 · SCHEDULE 13D/A, 2026-11-06
- · Reporting person: BlackRock, Inc. · Sole voting: 20,560,285 · Shared voting: 0 · Sole dispositive: 20,905,681 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-10-27
- · Reporting person: State Street Corporation · Sole voting: 0 · Shared voting: 9,678,303 · Sole dispositive: 0 · Shared dispositive: 9,964,151 · SCHEDULE 13G, 2026-08-07
- · Reporting person: Vanguard Portfolio Management · Sole voting: 59,162 · Shared voting: 0 · Sole dispositive: 11,554,377 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-07-31
- · Reporting person: SB Investment Advisers (UK) Limited · Sole voting: 0 · Shared voting: 10,948,093 · Sole dispositive: 0 · Shared dispositive: 10,948,093 · SCHEDULE 13G/A, 2026-05-15
Vir Biotechnology, Inc. has 9 Schedule 13D or 13G filings on record since 2026-02-17. 5 holders' latest filing reports 5% or more of common stock, $0.0001 par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| BlackRock, Inc. | 12.4% | 20,905,681 | SCHEDULE 13G/A, 2026-10-27 | 2026-09-30 |
| ARCH Venture Fund IX, L.P. | 7.3% | 11,897,988 | SCHEDULE 13D/A, 2026-11-06 | 2026-11-04 |
| Vanguard Portfolio Management | 6.85% | 11,554,377 | SCHEDULE 13G/A, 2026-07-31 | 2026-06-30 |
| SB Investment Advisers (UK) Limited | 6.5% | 10,948,093 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| State Street Corporation | 5.9% | 9,964,151 | SCHEDULE 13G, 2026-08-07 | 2026-06-30 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
Holding shares or following this stake? See who's behind Vir Biotechnology, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Vir Biotechnology, Inc. and the records around it.
Vir Biotechnology, Inc. elsewhere on the record
- Leadership changes Jul 2026
- Who owns it
Companies that share a holder
- ARCH Venture Fund IX, L.P. also filed stake reports on 2 other companies: Sana Biotechnology, Inc. (Aug 2026), Lyell Immunopharma, Inc. (May 2026)
- SB Investment Advisers (UK) Limited also filed stake reports on 5 other companies: Energy Vault Holdings, Inc. (May 2026), Compass, Inc. (Feb 2026), Roivant Sciences Ltd. (Feb 2026)
- STATE STREET CORPORATION also filed stake reports on 343 other companies: TRADE DESK INC/THE (Oct 2026), CENTRUS ENERGY CORP (Sep 2026), ACADIA PHARMACEUTICALS INC (Aug 2026)
Watch Vir Biotechnology, Inc.
Get an email when Vir Biotechnology, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Vir Biotechnology, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Vir Biotechnology, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Vir Biotechnology, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| BlackRock, Inc. | 20,560,285 | 0 | 20,905,681 | 0 | SCHEDULE 13G/A, 2026-10-27 |
| ARCH Venture Fund IX, L.P. | 0 | 11,897,988 | 0 | 11,897,988 | SCHEDULE 13D/A, 2026-11-06 |
| ARCH Venture Fund IX Overage, L.P. | 0 | 11,897,988 | 0 | 11,897,988 | SCHEDULE 13D/A, 2026-11-06 |
| ARCH Venture Partners IX, L.P. | 0 | 11,897,988 | 0 | 11,897,988 | SCHEDULE 13D/A, 2026-11-06 |
| ARCH Venture Partners IX Overage, L.P. | 0 | 11,897,988 | 0 | 11,897,988 | SCHEDULE 13D/A, 2026-11-06 |
| ARCH Venture Partners IX, LLC | 0 | 11,897,988 | 0 | 11,897,988 | SCHEDULE 13D/A, 2026-11-06 |
| Robert Nelsen | 576,148 | 11,931,881 | 576,148 | 11,931,881 | SCHEDULE 13D/A, 2026-11-06 |
| Keith Crandell | 272,964 | 11,897,988 | 272,964 | 11,897,988 | SCHEDULE 13D/A, 2026-11-06 |
| Clinton Bybee | 30,570 | 11,959,148 | 30,570 | 11,959,148 | SCHEDULE 13D/A, 2026-11-06 |
| Vanguard Portfolio Management | 59,162 | 0 | 11,554,377 | 0 | SCHEDULE 13G/A, 2026-07-31 |
| SB Investment Advisers (UK) Limited | 0 | 10,948,093 | 0 | 10,948,093 | SCHEDULE 13G/A, 2026-05-15 |
| SoftBank Vision Fund (AIV M1) L.P. | 0 | 10,948,093 | 0 | 10,948,093 | SCHEDULE 13G/A, 2026-05-15 |
| SVF Endurance (Cayman) Limited | 0 | 10,948,093 | 0 | 10,948,093 | SCHEDULE 13G/A, 2026-05-15 |
| State Street Corporation | 0 | 9,678,303 | 0 | 9,964,151 | SCHEDULE 13G, 2026-08-07 |
The latest filing identifies Vir Biotechnology, Inc. by CUSIP 92764N102 and gives its principal executive office as 1800 Owens Street, Suite 900, San Francisco, CA 94158 (SCHEDULE 13D/A, 2026-11-06).
Purpose of Transaction (Item 4)
ARCH Venture Fund IX, L.P.
Each of AVF IX and AVF IX Overage acquired the Common Stock for investment purposes. Depending on market conditions, the continuing evaluation of the business and prospects of the Issuer and other factors, AVF IX and AVF IX Overage and other Reporting Persons may dispose of or acquire additional shares of Common Stock of the Issuer. From November 3, 2026 to November 5, 2026, AVF IX and AVF IX Overage sold 347,819 shares and 448,356 shares respectively, of Common Stock for cash. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) Any material change in the present capitalization or dividend policy of the Issuer; (f) Any other material change in the Issuer's business or corporate structure; (g) Changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-11-06; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-02-17 | SB Investment Advisers (UK) Limited | 9.4% | SCHEDULE 13G/A |
| 2026-03-03 | ARCH Venture Fund IX, L.P. | 8.5% | SCHEDULE 13D/A |
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-29 | Vanguard Portfolio Management | 5.79% | SCHEDULE 13G |
| 2026-05-15 | SB Investment Advisers (UK) Limited | 6.5% | SCHEDULE 13G/A |
| 2026-07-31 | Vanguard Portfolio Management | 6.85% | SCHEDULE 13G/A |
| 2026-08-07 | State Street Corporation | 5.9% | SCHEDULE 13G |
| 2026-10-27 | BlackRock, Inc. | 12.4% | SCHEDULE 13G/A |
| 2026-11-06 | ARCH Venture Fund IX, L.P. | 7.3% | SCHEDULE 13D/A |
Questions about who owns Vir Biotechnology, Inc.
Who owns Vir Biotechnology, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Vir Biotechnology, Inc.: BlackRock, Inc. (12.4%, Schedule 13G/A, filed 2026-10-27), ARCH Venture Fund IX, L.P. (7.3%, Schedule 13D/A, filed 2026-11-06), Vanguard Portfolio Management (6.85%, Schedule 13G/A, filed 2026-07-31), SB Investment Advisers (UK) Limited (6.5%, Schedule 13G/A, filed 2026-05-15) and State Street Corporation (5.9%, Schedule 13G, filed 2026-08-07).
Who are the largest shareholders of Vir Biotechnology, Inc.?
By the share each holder's latest filing reports, the largest holders of Vir Biotechnology, Inc. on this page are BlackRock, Inc. (12.4%), ARCH Venture Fund IX, L.P. (7.3%) and Vanguard Portfolio Management (6.85%).
When did BlackRock, Inc. buy into Vir Biotechnology, Inc.?
The filings give report dates, not purchase dates. The earliest filing from BlackRock, Inc. on this page is the Schedule 13G/A, filed 2026-10-27, reporting 12.4%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Vir Biotechnology, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 28, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| October 1, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| July 24, 2026 | Leadership change: Brent Sabatini appointed, Chief Accounting Officer | — | Leadership changes | Source |
| June 10, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| May 28, 2026 | Leadership change: Saira Ramasastry departs, Director | — | Leadership changes | Source |
| April 10, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Vir Biotechnology, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.